Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Annals of Surgical Oncology|October 10, 2014
Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapyBeyhan Ataseven, Bianca Lederer, Jens U Blohmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2011
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO studyBernd Gerber, Gunter von Minckwitz, Heinrich Stehle, et al.
Annals of Surgical Oncology|July 11, 2013
Breast cancer mastectomy trends between 2006 and 2010: association with magnetic resonance imaging, immediate breast reconstruction, and hospital volumeJoerg Heil, Geraldine Rauch, Akos Z Szabo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
BMC Cancer|July 9, 2016
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trialJulia Jueckstock, Brigitte Rack, Thomas W P Friedl, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
European Journal of Cancer (Oxford, England : 1990)|September 20, 2017
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)Sibylle Loibl, Lorena de la Pena, Valentina Nekljudova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyMichael Untch, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro studyGunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, et al.
Pageof 8